GlyTherix

The page describes GlyTherix’s Glypican-1 (GPC-1) antibody as a targeted therapy for delivering a radioactive payload to cancer cells.

Miltuximab is a patented GlyTherix antibody that targets Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, glioblastoma, esophageal, and other solid tumors.

Companies are pleased to announce a co-development agreement that could result in a promising new CAR-T therapy for some solid cancers

A consortium led by the company are the successful recipients of a competitive grant in Round 9 of the Federal Government’s CRC-P program.

GlyTherix received a $50,000 COVID-19 TechVoucher from the NSW Government to collaborate with ANSTO’s radiochemistry and preclinical imaging teams.

GlyTherix board of knowledgeable and experienced managers.

GlyTherix draws on expertise from internationally esteemed medical experts on its Clinical Advisory Panel.

GlyTherix Ltd announced that another clinician joined its advisory board.

The company develops cancer therapeutics and is testing technologies to target tumors for cancer treatment.

Glypican-1 (GPC-1) is a cell surface proteoglycan overexpressed in multiple solid tumours, including bladder, breast, cervical, and pancreatic cancers.

GlyTherix is an immuno-oncology company specializing in cancer therapeutics, with intellectual property for treating solid tumors to improve patient outcomes.

GlyTherix obtains a Canadian patent for its antibody-drug conjugate (ADC) technology. The company develops targeted cancer therapies using ADCs to deliver cytotoxic agents directly to tumor cells. This patent strengthens GlyTherix’s intellectual property portfolio in precision oncology.

Jun 2026GlyTherixNews article

GlyTherix partners with Isotopia to accelerate radiopharmaceutical development. The collaboration focuses on integrating GlyTherix’s targeted therapies with Isotopia’s isotope production capabilities. Together, they aim to improve precision in cancer treatments by combining advanced molecular designs with optimized radionuclide supply chains.

May 2025GlyTherixNews article

GlyTherix and Eckert & Ziegler have extended their partnership to include a new supply agreement for **actinium-225**, a radioactive isotope used in targeted cancer therapies. The collaboration aims to secure a stable supply chain for GlyTherix’s **Glypican-1** targeted treatment pipeline. Both companies specialize in advancing radiopharmaceutical solutions for precision oncology.

Jan 2025GlyTherixNews article

GlyTherix Ltd partners with 3D Imaging LLC to develop and manufacture radiopharmaceuticals in the U.S. The collaboration leverages GlyTherix’s antibody-based cancer therapies and 3D Imaging’s expertise in radiopharmaceutical production. This agreement aims to accelerate the advancement of targeted radiotherapy treatments.

Jan 2025newswire.comNews article